Ekso Bionics (NASDAQ:EKSO)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Friday, AnalystRatings.com reports. They currently have a $12.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 84.05% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Aegis reduced their price target on shares of Ekso Bionics from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, May 21st. ValuEngine raised shares of Ekso Bionics from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Finally, Zacks Investment Research cut shares of Ekso Bionics from a “buy” rating to a “hold” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $9.25.

Shares of Ekso Bionics stock traded down $0.84 during trading on Friday, hitting $6.52. 634,040 shares of the stock were exchanged, compared to its average volume of 515,526. The firm’s 50-day moving average price is $6.52 and its 200 day moving average price is $3.08. Ekso Bionics has a 12-month low of $2.25 and a 12-month high of $18.15. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.86 and a quick ratio of 1.53.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($1.32). The firm had revenue of $2.26 million for the quarter, compared to analysts’ expectations of $1.85 million. Ekso Bionics had a negative return on equity of 206.13% and a negative net margin of 156.16%. Equities analysts expect that Ekso Bionics will post -1.98 EPS for the current fiscal year.

An institutional investor recently bought a new position in Ekso Bionics stock. Strategic Wealth Designers acquired a new stake in Ekso Bionics Holdings Inc (NASDAQ:EKSO) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 13,550 shares of the company’s stock, valued at approximately $114,000. Strategic Wealth Designers owned about 0.18% of Ekso Bionics as of its most recent SEC filing. Institutional investors and hedge funds own 15.25% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.

Recommended Story: Management Fee

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.